Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells

Journal of Immunology

Volumn 160, Issue 12, 1998, Pages 6128-6136

  Hindmarsh, Elizabeth J ^a   Marks, Rory M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; GAMMA INTERFERON; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT PATHWAY, ALTERNATIVE; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MICROSCOPY, FLUORESCENCE;

EID: 0032526881     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Jaffe, E. A. 1992. Physiologic functions of normal endothelial cells. In Vascular Medicine. J. Loscalzo, M. A. Creager, and V. J. Dzau, eds. Little, Brown and Company, Boston, p. 3.
2. Marks, R. M., R. F. Todd III, and P. A. Ward. 1989. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 339:314.
3. Foreman, K. E., A. A. Vaporciyan, B. K. Bonish, M. L. Jones, K. J. Johnson, M. M. Glovsky, S. M. Eddy, and P. A. Ward. 1994. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest 94:1147.
4. Kilgore, K. S., J. P. Shen, B. F. Miller, P. A. Ward, and J. S. Warren. 1995. Enhancement by the complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J. Immunol. 155:1434.
5. Chenoweth, D. E. 1986. Complement mediators of inflammation. In Immunobiology of the Complement System. G. D. Ross, ed. Academic Press, Orlando, p. 63.
6. Biesecker, G., S. Katz, and D. Koffler. 1981. Renal localization of the membrane attack complex in systemic lupus erythematosus. J. Exp. Med. 154:1779.
7. Kissel, J. T., J. R. Mendell, and K. W. Rammohan. 1986. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314:329.
8. McManus, L. M., W. P. Kolb, M. H. Crawford, R. A. O'Rourke, F. L. Grover, and R. N. Pinckard. 1983. Complement localization in ischemic baboon myocardium. Lab. Invest. 48:436.
9. Cines, D. B., A. P. Lyss, M. Reeber, M. Bina, and R. J. DeHoratius. 1984. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J. Clin. Invest. 73:611.
10. Marks, R. M., M. Czerniecki, B. S. Andrews, and R. Penny. 1988. The effects of scleroderma serum on human microvascular endothelial cells: induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum. 31:1524.
11. Cervera, R., G. Ramirez, J. Fernandez-Sola, D. D'Cruz, J. Casademont, J. M. Grau, R. A. Asherson, M. A. Khamashta, A. Urbano-Marquez, and G. R. Hughes. 1991. Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease. Br. Med. J. 302:880.
12. Trento, A., R. L. Hardesty, B. P. Griffith, T. Zerbe, R. L. Kormos, and H. T. Bahnson. 1988. Role of the antibody to vascular endothelial cells in hyperacute rejection in patients undergoing cardiac transplantation. J. Thorac. Cardiovasc. Surg. 95:37.
13. Wang, X. M., H. P. Zhong, S. F. Zhou, and J. P. Chen. 1989. Detection of anti-vascular endothelial cell antibodies with microcytotoxicity testing. J. Clin. Lab. Immunol. 28:73.
14. Ley, K. 1996. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc. Res. 32:733.
15. Jaffe, E. A. 1984. Culture and identification of large vessel endothelial cells. In Biology of Endothelial Cells. E. A. Jaffe, ed. Martinus Nijhoff, The Hague, p. 1.
16. Lichtenfels, R., W. E. Biddison, H. Schulz, A. B. Vogt, and R. Martin. 1994. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J. Immunol. Methods 172:227.
17. Montesano, R., A. Mossaz, J.-E. Ryser, L. Orci, and P. Vassalli. 1984. Leukocyte interleukins induce cultured endothelial cells to produce a highly organized, glycosaminoglycan-rich pericellular matrix. J. Cell Biol. 99:1706.
18. Montesano, R., L. Orci, and P. Vassalli. 1985. Human endothelial cell cultures: phenotypic modulation by leukocyte interleukins. J. Cell. Physiol. 122:424.
19. Stolpen, A. H., E. C. Guinan, W. Fiers, and J. S. Pober. 1986. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol. 123:16.
20. Kagiyama, A., H. E. Savage, L. H. Michael, G. Hanson, M. L. Entman, and R. D. Rossen. 1989. Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human C1q and fix complement. Circ. Res. 64:607.
21. Rus, H. G., F. Niculescu, E. Constantinescu, A. Cristea, and R. Vlaicu. 1986. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 61:35.
22. Haugland, R. P. 1996. Fluorescent tracers of cell morphology and fluid flow. In Handbook of Fluorescent Probes and Research Chemicals. Molecular Probes, Eugene, OR, p. 344.
23. Preissner, K. T., and D. Jenne. 1991. Vitronectin: a new molecular connection in haemostasis. Thromb. Haemost. 66:189.
24. Preissner, K. T., J. Grulich-Henn, H. J. Ehrlich, P. Declerck, C. Justus, D. Collen, H. Pannekoek, and G. Muller-Berghaus. 1990. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J. Biol. Chem. 265:18490.
25. Postlethwaite, A. E., and A. H. Kang. 1992. Fibroblasts and matrix proteins. In Inflammation: Basic Principles and Clinical Correlates. J. I. Gallin, I. M. Goldstein, and R. Snyderman, eds. Raven Press, New York, p. 747.
26. Yurchenco, P. D., and J. C. Schittny. 1990. Molecular architecture of basement membranes. FASEB J. 4:1577.
27. Pangburn, M. K. 1986. The alternative pathway. In Immunobiology of the Complement System. G. D. Ross, ed. Academic Press, Orlando, p. 45.
28. Berger, M. 1990. Third component of human complement: C3. Methods Enzymol 184:619.
29. Podack, E. R. 1986. Assembly and functions of the terminal components. In Immunobiology of the Complement System. G. D. Ross, ed. Academic Press, Orlando, p. 115.
30. Hanauske-Abel, H. M., B. F. Pontz, and H. U. Schorlemmer. 1982. Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoid arthritis. Ann. Rheum. Dis. 41:168.
31. Williams, J. D., J. K. Czop, D. R. Abrahamson, M. Davies, and K. F. Austen. 1984. Activation of the alternative complement pathway by isolated glomerular basement membrane. J. Immunol. 133:394.
32. Loos, M., and D. Bitter-Suermann. 1976. Mode of interaction of different polyanions with the first (C1) the second (C2) and the fourth (C4) component of complement. IV. Activation of Cl in serum by polyanions. Immunology 31:931.
33. Burger, R., D. Bitter-Suermann, M. Loos, and U. Hadding. 1977. Insoluble polyanions as activators of both pathways of complement. Immunology 33:827.
34. Pangburn, M. K., and H. J. Muller-Eberhard. 1980. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 152:1102.
35. Sahu, A., T. R. Kozel, and M. K. Pangburn. 1994. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem. J. 302:429.
36. Law, S. K. A., and K. B. M. Reid. 1988. Complement. IRL Press, Oxford, U.K.
37. Goldstein, I. M. 1992. Complement. Biologically active products. In Inflammation: Basic Principles and Clinical Correlates. J. I. Gallin, I. M. Goldstein, and R. Snyderman, eds. Raven Press, New York, p. 63.
38. Martin, U., D. Bock, L. Arseniev, M. A. Tornetta, R. S. Ames, W. Bautsch, J. Kohl, A. Ganser, and A. Klos. 1997. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J. Exp. Med. 186:199.
39. Takabayashi, T., E. Vannier, B. D. Clark, N. H. Margolis, C. A. Dinarello, J. F. Burke, and J. A. Gelfand. 1996. A new biologic role for C3a and C3a desArg: regulation of TNF-α and IL-1β synthesis. J. Immunol. 156:3455.
40. Mousli, M., T. E. Hugli, Y. Landry, and C. Bronner. 1992. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol 148:2456.
41. Kretzschmar, T., A. Jeromin, C. Gietz, W. Bautsch, A. Klos, J. Kohl, G. Rechkemmer, and D. Bitter-Suermann. 1993. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur. J. Immunol. 23:558.
42. 2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. Eur. J. Biochem. 217:289.
43. Elsner, J., M. Oppermann, W. Czech, and A. Kapp. 1994. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83:3324.
44. Elsner, J., M. Oppermann, W. Czech, G. Dobos, E. Schopf, J. Norgauer, and A. Kapp. 1994. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur. J. Immunol. 24:518.
45. Daffern, P. J., P. H. Pfeifer, J. A. Ember, and T. E. Hugli, 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils: C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181:2119.
46. Nilsson, G., M. Johnell, C. H. Hammer, H. L. Tiffany, K. Nilsson, D. D. Metcalfe, A. Siegbahn, and P. M. Murphy. 1996. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157:1693.
47. Majno, G., S. M. Shea, and M. Leventhal. 1969. Endothelial contraction induced by histamine-type mediators: an electron microscopic study. J. Cell Biol. 42:647.
48. Remick, D. G., R. G. Kunkel, J. W. Larrick, and S. L. Kunkel. 1987. Acute in vivo effects of human recombinant tumor necrosis factor. Lab. Invest. 56:583.
49. Goldblum, S. E., K. Yoneda, D. A. Cohen, and C. J. McClain. 1988. Provocation of pulmonary vascular endothelial injury in rabbits by human recombinant interleukin-1β. Infect. Immun. 56:2255.
50. Stephens, K. E., A. Ishizaka, J. W. Larrick, and T. A. Raffin. 1988. Tumor necrosis factor causes increased pulmonary permeability and edema: comparison to septic lung injury. Am. Rev. Respir. Dis. 137:1364.
51. Goldblum, S. E., B. Hennig, M. Jay, K. Yoneda, and C.J. McClain. 1989. Tumor necrosis factor α-induced pulmonary vascular endothelial injury. Infect. Immun. 57:1218.
52. Cotran, R. S., and J. P. Remensnyder. 1968. The structural basis of increased vascular permeability after graded thermal injury-light and electron microscopic studies. Ann. NY Acad. Sci. 150:495.
53. Richman, A. V., L. I. Gerber, and J. U. Balis. 1980. Peritubular capillaries: a major target site of endotoxin-induced vascular injury in the primate kidney. Lab. Invest. 43:327.
54. Turek, J. J., C. B. Templeton, G. D. Bottoms, and J. F. Fessler. 1985. Flunixin meglumine attenuation of endotoxin-induced damage to the cardiopulmonary vascular endothelium of the pony. Am. J. Vet. Res. 46:591.
55. Cupps, T. R., and A. S. Fauci. 1981. Pathophysiology of vasculitis. In The Vasculitides. Vol. 21. L. H. Smith, ed. W. B. Saunders, Philadelphia, p. 6.
56. Dabareiner, R. M., J. R. Snyder, N. A. White, J. R. Pascoe, F. A. Harmon, I. Gardner, M. J. Woliner, D. Pinney, and K. E. Sullins. 1995. Microvascular permeability and endothelial cell morphology associated with low-flow ischemia/reperfusion injury in the equine jejunum. Am. J. Vet. Res. 56:639.
57. Ferns, G. A., A. L. Stewart-Lee, and E. E. Anggard. 1992. Arterial response to mechanical injury: balloon catheter de-endothelialization. Atherosclerosis 92:89.
58. Gelfand, J. A., M. Donelan, A. Hawiger, and J. F. Burke. 1982. Alternative complement pathway activation increases mortality in a model of burn injury in mice. J. Clin. Invest. 70:1170.
59. Smedegard, G., L. X. Cui, and T. E. Hugli. 1989. Endotoxin-induced shock in the rat: a role for C5a. Am. J. Pathol. 135:489.
60. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
61. Lin, R. Y., M. E. Astiz, J. C. Saxon, D. C. Saha, and E. C. Rackow. 1993. Alterations in C3, C4, factor B. and related metabolites in septic shock. Clin. Immunol. Immunopathol. 69:136.
62. Kilgore, K. S., G. S. Friedrichs, J. W. Homeister, and B. R. Lucchesi. 1994. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 28:437.
63. Hsueh, W., X. Sun, L. N. Rioja, and F. Gonzalez-Crussi. 1990. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 70:309.
64. Vachino, G., J. A. Gelfand, M. B. Atkins, J. D. Tamerius, P. Demchak, and J. W. Mier. 1991. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 78:2505.
65. Hindmarsh, E. J., and R. M. Marks. 1998. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur. J. Immunol. 28:1052.